Vertex EVP granted 8,682 restricted stock units

Vertex EVP Jasper van Grunsven received a 8,682-share restricted stock unit grant that begins vesting on September 8, 2027.

Rhea-AI Filing Summary

VERTEX PHARMACEUTICALS INC / MA (symbol: VRTX) is the issuer of record for a Form 4 filing submitted to the SEC. van Grunsven Jasper reported acquisition or exercise transactions in this Form 4 filing.

VERTEX PHARMACEUTICALS INC / MA (VRTX) reported that executive vice president Jasper van Grunsven received an award of 8,682 shares of common stock on September 8, 2026, as a stock-based compensation grant at no cash purchase price.

The award is in the form of restricted stock units that vest in installments beginning on September 8, 2027. After this grant, he is reported as directly holding 8,682 common shares. No transactions were reported under a Rule 10b5-1 trading plan.

Insider Trade Summary

Grant/Award: 8,682 shares

Grant/Award 1 txn

Insider van Grunsven Jasper

Role EVP, CP and NPPO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	8,682	$0.00	$0.00

Holdings After Transaction: Common Stock — 8,682 shares (Direct)

Footnotes (1)

1. F1. Restricted stock unit award that vests in installments beginning on 09/08/2027.

Key Figures

Restricted stock units granted: 8,682 shares Grant price per share: $0.00 per share Shares held after transaction: 8,682 shares +2 more

5 metrics

Restricted stock units granted 8,682 shares Equity award granted on September 8, 2026

Grant price per share $0.00 per share Stock-based compensation grant, not a market purchase

Shares held after transaction 8,682 shares Direct common stock holdings reported for Jasper van Grunsven after the grant

Vesting start date September 8, 2027 Restricted stock units vest in installments beginning on this date

Number of acquire-type transactions 1 transaction Single grant or award acquisition reported in this Form 4

Key Terms

Restricted stock unit, vests in installments, stock-based compensation

3 terms

Restricted stock unit financial

"Restricted stock unit award that vests in installments beginning on 09/08/2027."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vests in installments financial

"Restricted stock unit award that vests in installments beginning on 09/08/2027."

stock-based compensation financial

"award of 8,682 shares of common stock on September 8, 2026, as a stock-based compensation grant"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

FAQ

What insider transaction did VRTX disclose for Jasper van Grunsven?

Vertex reported that Jasper van Grunsven received an award of 8,682 shares of common stock on September 8, 2026, as a stock-based compensation grant at no cash purchase price, structured as restricted stock units that vest over time.

What type of shares were granted to the Vertex (VRTX) executive?

The executive vice president received an award of restricted stock units (RSUs) representing 8,682 shares of Vertex common stock, granted on September 8, 2026, as equity compensation rather than a market purchase.

When do the new Vertex (VRTX) restricted stock units start vesting?

The filing states that the restricted stock unit award vests in installments beginning on September 8, 2027. The vesting occurs over time from that date, subject to the award’s terms and any continued service conditions.

How many Vertex (VRTX) shares does Jasper van Grunsven hold after this grant?

After the reported grant, Jasper van Grunsven is shown as directly holding 8,682 shares of Vertex common stock, reflecting the full amount of the new restricted stock unit award.

Was the Vertex (VRTX) insider grant made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan was reported in connection with this restricted stock unit grant to the executive vice president.

What is Jasper van Grunsven’s role at Vertex (VRTX) in this Form 4?

The reporting person, Jasper van Grunsven, is identified as an executive vice president, CP and NPPO of Vertex Pharmaceuticals, and the reported transaction relates to his equity compensation in that role.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:32 PM Accepted by SEC EDGAR 09/10/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van Grunsven Jasper

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CP and NPPO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		A		8,682(1)	A	$0	8,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award that vests in installments beginning on 09/08/2027.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)